SunTrust Banks reaffirmed their buy rating on shares of Icon (NASDAQ:ICLR) in a research report sent to investors on Monday morning. SunTrust Banks currently has a $133.00 target price on the medical research company’s stock. SunTrust Banks also issued estimates for Icon’s Q4 2017 earnings at $1.42 EPS, FY2017 earnings at $5.25 EPS, FY2018 earnings at $6.08 EPS and FY2019 earnings at $6.96 EPS.

ICLR has been the topic of a number of other research reports. Zacks Investment Research lowered Icon from a hold rating to a sell rating in a research report on Wednesday, October 4th. Credit Suisse Group reaffirmed an outperform rating and set a $120.00 price target (up previously from $105.00) on shares of Icon in a research report on Monday, October 16th. KeyCorp reaffirmed an overweight rating and set a $125.00 price target (up previously from $115.00) on shares of Icon in a research report on Monday, November 13th. They noted that the move was a valuation call. ValuEngine raised Icon from a hold rating to a buy rating in a research report on Sunday, December 31st. Finally, Evercore ISI initiated coverage on Icon in a research report on Thursday, January 18th. They set an outperform rating and a $126.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $124.45.

Shares of Icon (NASDAQ:ICLR) traded down $1.29 on Monday, reaching $112.68. The company’s stock had a trading volume of 280,700 shares, compared to its average volume of 298,921. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. Icon has a 12-month low of $76.46 and a 12-month high of $124.48. The company has a market capitalization of $6,170.00, a PE ratio of 21.88, a P/E/G ratio of 1.62 and a beta of 0.61.

Icon (NASDAQ:ICLR) last issued its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. Icon had a return on equity of 28.42% and a net margin of 16.37%. The firm had revenue of $440.30 million for the quarter, compared to analysts’ expectations of $438.09 million. During the same quarter last year, the business earned $1.19 earnings per share. The company’s revenue was up 4.8% compared to the same quarter last year. equities analysts expect that Icon will post 5.37 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. IHT Wealth Management LLC raised its position in Icon by 16.9% in the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock valued at $223,000 after buying an additional 24 shares during the last quarter. Bangor Savings Bank raised its position in Icon by 1.4% in the 2nd quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock valued at $1,128,000 after buying an additional 161 shares during the last quarter. D.A. Davidson & CO. raised its position in Icon by 7.8% in the 2nd quarter. D.A. Davidson & CO. now owns 4,761 shares of the medical research company’s stock valued at $465,000 after buying an additional 345 shares during the last quarter. MML Investors Services LLC raised its position in Icon by 9.0% in the 2nd quarter. MML Investors Services LLC now owns 4,983 shares of the medical research company’s stock valued at $487,000 after buying an additional 413 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in Icon by 11.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,844 shares of the medical research company’s stock valued at $474,000 after buying an additional 481 shares during the last quarter. 89.65% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/icons-iclr-buy-rating-reaffirmed-at-suntrust-banks/1820276.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.